SRPT - サレプタ・セラピュ―ティックス (Sarepta Therapeutics Inc.) サレプタ・セラピュ―ティックス

 SRPTのチャート


 SRPTの企業情報

symbol SRPT
会社名 Sarepta Therapeutics Inc (サレプタ・セラピュ―ティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 サレプタ・セラピューティクス(Sarepta Therapeutics Inc.)はバイオ医薬品会社である。同社は希少神経筋疾患の治療用のリボ核酸(RNA)標的治療法の発見・開発に従事する。同社はデュシェンヌ型筋ジストロフィー(DMD)患者の治療法の発見・開発・製造・提供を通じて運営する。同社はその疾患修飾性DMD薬候補の開発に焦点を当てる。同社はエキソン51のスキッピングを受けやすいDMD遺伝子の突然変異が確認された患者のDMD治療について示された製品EXONDYS 51の承認が早まった。EXONDYS 51は、「eteplirsen」の名で臨床試験中に研究されている。その次世代のホスホロジアミデートモルホリノオリゴマー(PMO)ベースの化合物は、標準的なワトソン - クリック核酸塩基対形成によってRNAの相補的配列に結合する合成化合物である。PMOに基づく化学は、ペプチド共役PMO(PPMO)、PMO-XおよびPMOplusである。   サレプタ・セラピュ―ティックスは米国のバイオ医薬品会社。奇病と伝染病両方の治療に用いる独自のRNA(リボ核酸)ベ―スの治療法発見と開発を手掛ける。また、マ―ルブルグ出血熱ウイルスのための薬剤候補AVI-7288や、H1N1インフルエンザ薬候補、エボラ出血熱ウィルスの薬剤候補の開発にも従事する。   Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.
本社所在地 215 First Street Suite 415 Cambridge MA 02142 USA
代表者氏名 M. Kathleen Behrens M.キャスリーン・ベーレンス
代表者役職名 Independent Chairwoman of the Board
電話番号 +1 617-274-4000
設立年月日 29403
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 255人
url www.sarepta.com
nasdaq_url https://www.nasdaq.com/symbol/srpt
adr_tso
EBITDA EBITDA(百万ドル) -167.82400
終値(lastsale) 131.18
時価総額(marketcap) 8715914294.36
時価総額 時価総額(百万ドル) 8917.899
売上高 売上高(百万ドル) 241.36400
企業価値(EV) 企業価値(EV)(百万ドル) 8408.194
当期純利益 当期純利益(百万ドル) -216.36200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Sarepta Therapeutics Inc revenues increased from $51.4M to $138.1M. Net loss totaled $144.6M vs. income of $21M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Gain from sale of Priority Review Vouche decrease from $125M (income) to $0K Research and development- other increase of 93% to $162M (expense).

 SRPTのテクニカル分析


 SRPTのニュース

   Sarepta Therapeutics Inc (SRPT): Price Now Near $68.32; Daily Chart Shows Downtrend on 20 Day Basis  2021/07/16 15:14:16 ETF Daily News
The moving averages on the daily timeframe suggest a bearishness in price, as the 20, 50, 100 and 200 are all in a bearish alignment -- meaning the shorter duration moving averages are below the longer duration averages, implying a stable downward trend. The post Sarepta Therapeutics Inc (SRPT): Price Now Near $68.32; Daily Chart Shows Downtrend on 20 Day Basis appeared first on ETF Daily News .
   The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs  2021/07/15 12:07:56 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) ( announced a registered direct offering) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) AlloVir, Inc. (NASDAQ: ALVR ) Aptose Biosciences Inc. (NASDAQ: APTO ) Avenue Therapeutics, Inc.
   Limb Girdle Muscular Dystrophy (LGMD) Market 2021 | Covid19 Impact Analysis | Size, Share, Sales and Forecast to 2026: Sarepta Therapeutics, aTyr Pharma, Myonexus Therapeutics, .. , , etc.  2021/07/09 11:10:53 Tramways Monthly
Global Limb Girdle Muscular Dystrophy (LGMD) Market 2021 report is comprised of an in-depth analysis of the global industry which aims to deliver comprehensive market intelligence study associated with major market components. The report includes an overview of these markets on different fronts such as market size, market share, market penetration of the product and []
   Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)  2021/07/06 13:48:39 Insider Monkey
   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/06/30 22:40:58 Benzinga
CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta''s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 2 individuals hired by Sarepta in June 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 2,450 shares of Sarepta''s common stock, and in the aggregate 1,250 restricted stock units ("RSUs"). The options have an exercise price of $77.74 per share, which is equal to the closing price of Sarepta''s common stock on June 30, 2021 Full story available on Benzinga.com
   Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)  2021/06/10 22:48:04 Seeking Alpha
   Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030  2021/06/09 09:33:00 Intrado Digital Media
Major players in the oligonucleotide therapy market are Alnylam Pharmaceuticals Inc. , Biogen Inc. , Dynavax Technologies Corp. , Ionis Pharmaceuticals Inc. , Merck & Co. Inc. , Miragen Therapeutics Inc. , PCI Biotech Holdings ASA, Sarepta Therapeutics Inc. Major players in the oligonucleotide therapy market are Alnylam Pharmaceuticals Inc. , Biogen Inc. , Dynavax Technologies Corp. , Ionis Pharmaceuticals Inc. , Merck & Co. Inc. , Miragen Therapeutics Inc. , PCI Biotech Holdings ASA, Sarepta Therapeutics Inc.
   Biotech Report: Sektor legt zu, Biogen und Sarepta Therapeutics nach der Rally  2021/06/08 12:42:00 FinanzNachrichten
(shareribs.com) Frankfurt / New York 08.06.2021 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend fester. Biontech und Qiagen legen hier zu. An der Wall Street kletterten Biogen im gestr
   Sarepta Therapeutics: Faultlines May Run Deeper Than Assumed  2021/06/02 08:13:06 Seeking Alpha
   Global $14.1 Billion Oligonucleotide Synthesis Market to 2026 Featuring Therapeutic Players - Biogen, Sarepta Therapeutics, Ionis Pharmaceuticals, & Alnylam Pharmaceuticals  2021/05/21 12:30:00 PR Newswire
DUBLIN, May 21, 2021 /PRNewswire/ -- The "Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global Forecast to
   Sarepta's Stock Trading Higher As Duchenne Muscular Dystrophy Gene Therapy Shows Promise In Open-Label Study  2021/05/18 18:02:22 Benzinga
Sarepta Therapeutics Inc (NASDAQ: SRPT ) has announced positive 12-week results from the first 11 participants enrolled in open-label study 9001-103 ENDEAVOR being conducted in partnership with Roche Holdings AG's (OTC: RHHBY ). Results demonstrated robust expression of micro-dystrophin and no new safety signals from prior … Full story available on Benzinga.com
   Monthly Dosing Of Sarepta's Next-Gen Eteplirsen Can Potentially Achieve Over 10% Higher Dystrophin Expression In DMD Patients  2021/05/03 17:22:45 Benzinga
Sarepta Therapeutics Inc (NASDAQ: SRPT ) announced positive results from Part A in a tiny group of 4 patients of the MOMENTUM Phase 2 study evaluating SRP-5051 in Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping. SRP-5051 is the company's next-generation peptide phosphorodiamidate morpholino oligomer (PPMO). At a median of week 12, 30 mg/kg of SRP-5051 resulted in mean dystrophin production of 6.55% of normal. Dystrophin expression was measured … Full story available on Benzinga.com
   RBC Capital Stick to Their Buy Rating for Sarepta Therapeutics By Investing.com  2021/04/12 01:46:09 Investing.com
RBC Capital Stick to Their Buy Rating for Sarepta Therapeutics
   Needham Stick to Their Buy Rating for Sarepta Therapeutics By Investing.com  2021/03/19 12:55:02 Investing.com
Needham Stick to Their Buy Rating for Sarepta Therapeutics
   The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs  2021/03/19 11:46:46 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 18) AngioDynamics, Inc. (NASDAQ: ANGO ) Anixa Biosciences, Inc. (NASDAQ: ANIX ) ENDRA Life Sciences Inc. (NASDAQ: NDRA ) (announced a collaboration with Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA ) for NASH studies) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Neos Therapeutics, Inc. (NASDAQ: NEOS ) (reacted to the shareholder meeting held to vote on the proposal to merge with Aytu BioScience, Inc. (NASDAQ: AYTU )) NuVasive, Inc. (NASDAQ: NUVA ) SI-BONE, Inc. (NASDAQ: SIBN ) Sierra Oncology, Inc. (NASDAQ: SRRA ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) Terns Pharmaceuticals, Inc. (NASDAQ: TERN ) Varian Medical Systems, Inc. (NASDAQ: VAR ) Vericel Corporation (NASDAQ: VCEL ) Vincerx Pharma, Inc. (NASDAQ: VINC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 18) Foghorn Therapeutics Inc. (NASDAQ: FHTX ) (issued a corporate update) Galecto, Inc. (NASDAQ: GLTO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus Sarepta Presents Positive Data For Gene Therapy to Treat Limb-gridle Muscular Dystrophy Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) announced new results from the ongoing study of SRP-9003, its investigational gene therapy for limb-girdle muscular dystrophy Type 2E, showing sustained protein expression in muscle tissue.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 サレプタ・セラピュ―ティックス SRPT Sarepta Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)